Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy

Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of tumor/immune/genome interactions. We implemented a multidisciplinary Molecular Tumor Board (MTB) that reviewed multi-omic cancer characteristics t...

Descripción completa

Detalles Bibliográficos
Autores principales: Louie, Bryan H., Kato, Shumei, Kim, Ki Hwan, Lim, Hyo Jeong, Okamura, Ryosuke, Eskander, Ramez N., Botta, Gregory, Patel, Hitendra, Lee, Suzanna, Lippman, Scott M., Sicklick, Jason K., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500013/
https://www.ncbi.nlm.nih.gov/pubmed/36138116
http://dx.doi.org/10.1038/s41698-022-00309-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500013/
https://www.ncbi.nlm.nih.gov/pubmed/36138116
http://dx.doi.org/10.1038/s41698-022-00309-0

Ejemplares similares